Huangming Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huangming Hong has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
He Huang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
11 shared publications- Tongyu Lin
Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan, China.
10 shared publications Le Yu
Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, People’s Republic of China
8 shared publicationsZhao Wang
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China
6 shared publicationsHongqiang Guo
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
5 shared publicationsHuageng Huang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
5 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1873-1892
ZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is a prevalent lethal cancer that remains challenging to treat. Therefore, investigation of novel targets and therapeutic strategies is essential. The role of ZBED4 in cancer remains unclear. Methods: Data were sourced from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), International Cancer Genome Consortium (ICGC), and Genomics of Drug Sensitivity in Cancer (GDSC) databases. Various web platforms and R software, have been utilized. Multiplex immunofluorescence was performed on a human HCC tissue microarray. Results: High ZBED4 expression correlates with poor prognosis and immune cell infiltration in multiple cancers. ZBED4 is potentially involved in the regulation of the tumor environment by T cells, with a focus on CD8⁺ T cells. In HCC, tissues with elevated ZBED4 expression exhibit a higher prevalence of Tregs and neutrophils, whereas those with reduced ZBED4 expression show an increased abundance of CD8⁺ T cells, activated CD4⁺ T cells, gamma/delta T cells, and activated natural killer (NK) cells. Elevated ZBED4 expression in HCC patients is associated with a reduced response to immune checkpoint blockade but an improved response to chemotherapy and most targeted therapies. A multi-gene prognostic signature has been developed and confirmed across various HCC cohorts. Multiplex immunofluorescence study demonstrated that ZBED4 was linked to poor prognosis and negatively correlated with CD8⁺ T cell infiltration. Conclusion: Our research elucidates the role of ZBED4, its strong link to immune infiltration, and its potential as a prognostic and therapeutic biomarker for HCC. Plain Language Summary: Why was this study done? Hepatocellular carcinoma (HCC) is a common and aggressive liver cancer with limited treatment options. The ZBED gene family plays roles in cancer progression, but the function of one member, ZBED4, was unknown. This study explored whether ZBED4 could serve as a biomarker to predict patient outcomes or guide therapies for HCC. What did the researchers do? We analyzed data from public cancer databases and patient tissue samples to investigate ZBED4’s role in HCC. We examined:How ZBED4 levels vary in tumors compared to normal tissues.Whether ZBED4 affects immune cells in the tumor environment.Its link to patient survival and response to treatments like chemotherapy and immunotherapy. What did we find?High ZBED4 levels were linked to worse survival and advanced cancer stages.Tumors with more ZBED4 had fewer cancer-fighting immune cells (like CD8⁺ T cells) and more immunosuppressive cells (like Tregs).ZBED4 may predict drug sensitivity: patients with high ZBED4 responded better to chemotherapy but poorly to immunotherapy.A 10-gene signature based on ZBED4-related genes helped identify high-risk HCC patients. What do these results mean? ZBED4 could be a useful biomarker to guide treatment decisions in HCC. Targeting ZBED4 might improve outcomes, though further research is needed to confirm this. Future basic and clinical studies should explore whether combining ZBED4-targeted therapies with immune-boosting treatments could enhance their effectiveness. Key terms explained:Biomarker: A measurable indicator of disease or treatment response.Immunotherapy: Treatments that help the immune system fight cancer.Tumor microenvironment (TME): The surrounding cells and molecules that influence tumor growth. This work opens new avenues of ZBED4 for personalized HCC therapy and highlights its importance in the tumor microenvironment and cancer progression.
- 1 August 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1873-1892
Open AccessZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is a prevalent lethal cancer that remains challenging to treat. Therefore, investigation of novel targets and therapeutic strategies is essential. The role of ZBED4 in cancer remains unclear. Methods: Data were sourced from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), International Cancer Genome Consortium (ICGC), and Genomics of Drug Sensitivity in Cancer (GDSC) databases. Various web platforms and R software, have been utilized. Multiplex immunofluorescence was performed on a human HCC tissue microarray. Results: High ZBED4 expression correlates with poor prognosis and immune cell infiltration in multiple cancers. ZBED4 is potentially involved in the regulation of the tumor environment by T cells, with a focus on CD8⁺ T cells. In HCC, tissues with elevated ZBED4 expression exhibit a higher prevalence of Tregs and neutrophils, whereas those with reduced ZBED4 expression show an increased abundance of CD8⁺ T cells, activated CD4⁺ T cells, gamma/delta T cells, and activated natural killer (NK) cells. Elevated ZBED4 expression in HCC patients is associated with a reduced response to immune checkpoint blockade but an improved response to chemotherapy and most targeted therapies. A multi-gene prognostic signature has been developed and confirmed across various HCC cohorts. Multiplex immunofluorescence study demonstrated that ZBED4 was linked to poor prognosis and negatively correlated with CD8⁺ T cell infiltration. Conclusion: Our research elucidates the role of ZBED4, its strong link to immune infiltration, and its potential as a prognostic and therapeutic biomarker for HCC. Plain Language Summary: Why was this study done? Hepatocellular carcinoma (HCC) is a common and aggressive liver cancer with limited treatment options. The ZBED gene family plays roles in cancer progression, but the function of one member, ZBED4, was unknown. This study explored whether ZBED4 could serve as a biomarker to predict patient outcomes or guide therapies for HCC. What did the researchers do? We analyzed data from public cancer databases and patient tissue samples to investigate ZBED4’s role in HCC. We examined:How ZBED4 levels vary in tumors compared to normal tissues.Whether ZBED4 affects immune cells in the tumor environment.Its link to patient survival and response to treatments like chemotherapy and immunotherapy. What did we find?High ZBED4 levels were linked to worse survival and advanced cancer stages.Tumors with more ZBED4 had fewer cancer-fighting immune cells (like CD8⁺ T cells) and more immunosuppressive cells (like Tregs).ZBED4 may predict drug sensitivity: patients with high ZBED4 responded better to chemotherapy but poorly to immunotherapy.A 10-gene signature based on ZBED4-related genes helped identify high-risk HCC patients. What do these results mean? ZBED4 could be a useful biomarker to guide treatment decisions in HCC. Targeting ZBED4 might improve outcomes, though further research is needed to confirm this. Future basic and clinical studies should explore whether combining ZBED4-targeted therapies with immune-boosting treatments could enhance their effectiveness. Key terms explained:Biomarker: A measurable indicator of disease or treatment response.Immunotherapy: Treatments that help the immune system fight cancer.Tumor microenvironment (TME): The surrounding cells and molecules that influence tumor growth. This work opens new avenues of ZBED4 for personalized HCC therapy and highlights its importance in the tumor microenvironment and cancer progression.
- Open Access
- 26 June 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1622691
Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma, characterized by an aggressive disease course and poor prognosis. The prognostic nutritional index (PNI), which reflects nutritional and immune status, has emerged as a potential prognostic factor in various cancers.Methods: In this multicenter retrospective study, a total of 173 patients with AITL between January 2010 and December 2022 were enrolled from three institutes in China. The optimal cutoff value for PNI was determined using the maximally selected rank statistics (MaxStat) analysis. The association of PNI and overall survival (OS) or progression free survival (PFS) was evaluated in univariable and multivariable Cox regression analyses. Receiver operating characteristic (ROC) curves were used to evaluate the prognostic performance and predictive accuracy of PNI combined with International Prognostic Index (IPI) and Prognostic Index for T-cell lymphoma (PIT).Results: Based on the MaxStat analysis, a score of 40.8 was identified as the optimal cutoff value for the PNI. Survival analysis revealed that the low PNI group had worse OS and PFS. The 3-year OS and PFS for the low PNI group were 27.5 and 26.5%, respectively, compared to 84.7 and 74.4% for the high PNI group (p < 0.001). Multivariate analyses indicated that PNI was significantly associated with both OS (HR 0.221, 95% CI 0.128–0.381, p < 0.001) and PFS (HR 0.380, 95% CI 0.242–0.596; p < 0.001). We further integrated PNI into the IPI and PIT prognostic models, and the predictive accuracy of both models was significantly improved.Conclusion: PNI is a simple and easily accessible prognostic indicator for AITL.
- 26 June 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1622691
Open AccessLow prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma, characterized by an aggressive disease course and poor prognosis. The prognostic nutritional index (PNI), which reflects nutritional and immune status, has emerged as a potential prognostic factor in various cancers.Methods: In this multicenter retrospective study, a total of 173 patients with AITL between January 2010 and December 2022 were enrolled from three institutes in China. The optimal cutoff value for PNI was determined using the maximally selected rank statistics (MaxStat) analysis. The association of PNI and overall survival (OS) or progression free survival (PFS) was evaluated in univariable and multivariable Cox regression analyses. Receiver operating characteristic (ROC) curves were used to evaluate the prognostic performance and predictive accuracy of PNI combined with International Prognostic Index (IPI) and Prognostic Index for T-cell lymphoma (PIT).Results: Based on the MaxStat analysis, a score of 40.8 was identified as the optimal cutoff value for the PNI. Survival analysis revealed that the low PNI group had worse OS and PFS. The 3-year OS and PFS for the low PNI group were 27.5 and 26.5%, respectively, compared to 84.7 and 74.4% for the high PNI group (p < 0.001). Multivariate analyses indicated that PNI was significantly associated with both OS (HR 0.221, 95% CI 0.128–0.381, p < 0.001) and PFS (HR 0.380, 95% CI 0.242–0.596; p < 0.001). We further integrated PNI into the IPI and PIT prognostic models, and the predictive accuracy of both models was significantly improved.Conclusion: PNI is a simple and easily accessible prognostic indicator for AITL.
- 13 January 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 685, 38-48
Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy
- 13 January 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 685, 38-48
Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy
- 26 June 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4231-4237
Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China
Approximately 40% of limited-stage (stage I and II) diffuse large B-cell lymphoma (LS-DLBCL) presents with extranodal disease. Extranodal LS-DLBCL may have significant biological differences and associated with worse outcomes than nodal disease. Although rituximab based chemoimmunotherapy is standard of first-line treatment, the role of consolidative radiotherapy (RT) in this particular subgroup is controversial. In this multicenter retrospective study, we evaluated the survival benefit of consolidative RT in patients diagnosed with extranodal LS-DLBCL and received rituximab-based chemoimmunotherapy with or without consolidative RT. A total of 328 patients were included, 129 patients (39.3%) received chemoimmunotherapy and consolidative RT, and 199 patients (60.7%) received chemoimmunotherapy alone. With a median follow-up of 5.1 years (range, 0.3–14.8 years), 5-year progression-free survival (PFS) and overall survival (OS) for all patients were 75.4% and 83.9%, respectively. In multivariate analyses, the addition of consolidative RT was associated with superior OS (P = 0.004) and PFS (P = 0.005). High stage-modified International Prognosis Index (SM-IPI) risk predicted worse OS (P = 0.001) and PFS (P = 0.005). Also, propensity score-matched analyses showed RT improved both OS (hazard ratio [HR] 0.228, 95% confidence index [CI] 0.111–0.467, P < 0.001) and PFS (HR 0.308, 95% CI 0.167–0.566, P < 0.001). Among patients who achieved CR, 49 patients (16.6%) developed disease relapse, of which 30.6% relapsed at local sites. Consolidative RT significantly reduced relapse risk (P = 0.002). Our results demonstrated that consolidative RT significantly improved outcomes in patients with extranodal LS-DLBCL in the rituximab era.
- 26 June 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4231-4237
Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China
Approximately 40% of limited-stage (stage I and II) diffuse large B-cell lymphoma (LS-DLBCL) presents with extranodal disease. Extranodal LS-DLBCL may have significant biological differences and associated with worse outcomes than nodal disease. Although rituximab based chemoimmunotherapy is standard of first-line treatment, the role of consolidative radiotherapy (RT) in this particular subgroup is controversial. In this multicenter retrospective study, we evaluated the survival benefit of consolidative RT in patients diagnosed with extranodal LS-DLBCL and received rituximab-based chemoimmunotherapy with or without consolidative RT. A total of 328 patients were included, 129 patients (39.3%) received chemoimmunotherapy and consolidative RT, and 199 patients (60.7%) received chemoimmunotherapy alone. With a median follow-up of 5.1 years (range, 0.3–14.8 years), 5-year progression-free survival (PFS) and overall survival (OS) for all patients were 75.4% and 83.9%, respectively. In multivariate analyses, the addition of consolidative RT was associated with superior OS (P = 0.004) and PFS (P = 0.005). High stage-modified International Prognosis Index (SM-IPI) risk predicted worse OS (P = 0.001) and PFS (P = 0.005). Also, propensity score-matched analyses showed RT improved both OS (hazard ratio [HR] 0.228, 95% confidence index [CI] 0.111–0.467, P < 0.001) and PFS (HR 0.308, 95% CI 0.167–0.566, P < 0.001). Among patients who achieved CR, 49 patients (16.6%) developed disease relapse, of which 30.6% relapsed at local sites. Consolidative RT significantly reduced relapse risk (P = 0.002). Our results demonstrated that consolidative RT significantly improved outcomes in patients with extranodal LS-DLBCL in the rituximab era.
- Open Access
- 22 April 2024
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 13 (1) , 1-4
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
- 22 April 2024
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 13 (1) , 1-4
Open AccessNovel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
- 16 April 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (7-8) , 1211-1231
Identifying SLC2A6 as the novel protective factor in breast cancer by TP53-related genes affecting M1 macrophage infiltration
The high heterogeneity of breast cancer (BC) caused by pathogenic gene mutations poses a challenge to immunotherapy, but the underlying mechanism remains unknown. The difference in the infiltration of M1 macrophages induced by TP53 mutations has a significant impact on BC immunotherapy. The aim of this study was to develop a TP53-related M1 macrophage infiltration molecular typing risk signature in BC and evaluate the biological functions of the key gene to find new immunotherapy biomarkers. Weighted correlation network analysis (WGCNA) and negative matrix factorization (NMF) were used for distinguishing BC subtypes. The signature and the nomogram were both constructed and evaluated. Biological functions of the novel signature gene SLC2A6 were confirmed through in vitro and in vivo experiments. RNA-Sequencing and protein profiling were used for detecting the possible mechanism of SLC2A6. The results suggested that four BC subtypes were distinguished by TP53-related genes that affect M1 macrophage infiltration. The signature constructed by molecular typing characteristics could evaluate BC's clinical features and tumor microenvironment. The nomogram could accurately predict the prognosis. The signature gene SLC2A6 was found to have an abnormally low expression in tumor tissues. Overexpression of SLC2A6 could inhibit proliferation, promote mitochondrial damage, and result in apoptosis of tumor cells. The HSP70 family member protein HSPA6 could bind with SLC2A6 and increase with the increased expression of SLC2A6. In summary, the risk signature provides a reference for BC risk assessment, and the signature gene SLC2A6 could act as a tumor suppressor in BC.
- 16 April 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (7-8) , 1211-1231
Identifying SLC2A6 as the novel protective factor in breast cancer by TP53-related genes affecting M1 macrophage infiltration
The high heterogeneity of breast cancer (BC) caused by pathogenic gene mutations poses a challenge to immunotherapy, but the underlying mechanism remains unknown. The difference in the infiltration of M1 macrophages induced by TP53 mutations has a significant impact on BC immunotherapy. The aim of this study was to develop a TP53-related M1 macrophage infiltration molecular typing risk signature in BC and evaluate the biological functions of the key gene to find new immunotherapy biomarkers. Weighted correlation network analysis (WGCNA) and negative matrix factorization (NMF) were used for distinguishing BC subtypes. The signature and the nomogram were both constructed and evaluated. Biological functions of the novel signature gene SLC2A6 were confirmed through in vitro and in vivo experiments. RNA-Sequencing and protein profiling were used for detecting the possible mechanism of SLC2A6. The results suggested that four BC subtypes were distinguished by TP53-related genes that affect M1 macrophage infiltration. The signature constructed by molecular typing characteristics could evaluate BC's clinical features and tumor microenvironment. The nomogram could accurately predict the prognosis. The signature gene SLC2A6 was found to have an abnormally low expression in tumor tissues. Overexpression of SLC2A6 could inhibit proliferation, promote mitochondrial damage, and result in apoptosis of tumor cells. The HSP70 family member protein HSPA6 could bind with SLC2A6 and increase with the increased expression of SLC2A6. In summary, the risk signature provides a reference for BC risk assessment, and the signature gene SLC2A6 could act as a tumor suppressor in BC.
- Open Access
- 30 March 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-8
Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma
Advanced diffuse large B cell lymphoma (DLBCL) is a common malignant tumor with aggressive clinical features and poor prognosis. At present, there is lack of effective prognostic tool for patients with advanced (stage III/IV) DLBCL. The aim of this study is to identify prognostic indicators that affect survival and response and establish the first survival prediction nomogram for advanced DLBCL. A total of 402 patients with advanced DLBCL were enrolled in this study. COX multivariate analysis was used to obtain independent prognostic factors. The independent prognostic factors were included in the nomogram, and the nomogram to predict the performance of the model was established by R rms package, C-index (consistency index), AUC curve and calibration curve. The training and validation cohorts included 281 and 121 patients. In the training cohort, multivariate analysis showed that Ki-67 (70% (high expression) vs ≤ 70% (low expression), p < 0.001), LDH (lactate dehydrogenase) (elevated vs normal, p = 0.05), FER (ferritin) (elevated vs normal, p < 0.001), and β2-microglobulin (elevated vs normal, p < 0.001) were independent predictors and the nomogram was constructed. The nomogram showed that there was a significant difference in OS among the low-risk, intermediate-risk and high-risk groups, with 5-year survival rates of 81.6%, 44% and 6%, respectively. The C-index of the nomogram in the training group was 0.76. The internal validation of the training group showed good consistency. In the internal validation cohort of the training group, the AUC was 0.828, and similar results were obtained in the validation group, with a C-index of 0.74 and an AUC of 0.803. The proposed nomogram provided a valuable individualized risk assessment of OS in advanced DLBCL patients.
- 30 March 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-8
Open AccessDevelopment and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma
Advanced diffuse large B cell lymphoma (DLBCL) is a common malignant tumor with aggressive clinical features and poor prognosis. At present, there is lack of effective prognostic tool for patients with advanced (stage III/IV) DLBCL. The aim of this study is to identify prognostic indicators that affect survival and response and establish the first survival prediction nomogram for advanced DLBCL. A total of 402 patients with advanced DLBCL were enrolled in this study. COX multivariate analysis was used to obtain independent prognostic factors. The independent prognostic factors were included in the nomogram, and the nomogram to predict the performance of the model was established by R rms package, C-index (consistency index), AUC curve and calibration curve. The training and validation cohorts included 281 and 121 patients. In the training cohort, multivariate analysis showed that Ki-67 (70% (high expression) vs ≤ 70% (low expression), p < 0.001), LDH (lactate dehydrogenase) (elevated vs normal, p = 0.05), FER (ferritin) (elevated vs normal, p < 0.001), and β2-microglobulin (elevated vs normal, p < 0.001) were independent predictors and the nomogram was constructed. The nomogram showed that there was a significant difference in OS among the low-risk, intermediate-risk and high-risk groups, with 5-year survival rates of 81.6%, 44% and 6%, respectively. The C-index of the nomogram in the training group was 0.76. The internal validation of the training group showed good consistency. In the internal validation cohort of the training group, the AUC was 0.828, and similar results were obtained in the validation group, with a C-index of 0.74 and an AUC of 0.803. The proposed nomogram provided a valuable individualized risk assessment of OS in advanced DLBCL patients.
- 20 February 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 829-839
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma
Natural killer/T-cell lymphoma (NKTCL) is a highly heterogeneous disease with a poor prognosis. However, the genomic characteristics and proper treatment strategies for non-upper aerodigestive tract NKTCL (NUAT-NKTCL), a rare subtype of NKTCL, remain largely unexplored. In this study, 1589 patients newly diagnosed with NKTCL at 14 hospitals were assessed, 196 (12.3%) of whom had NUAT-NKTCL with adverse clinical characteristics and an inferior prognosis. By using whole-genome sequencing (WGS) and whole-exome sequencing (WES) data, we found strikingly different mutation profiles between upper aerodigestive tract (UAT)- and NUAT-NKTCL patients, with the latter group exhibiting significantly higher genomic instability. In the NUAT-NKTCL cohort, 128 patients received frontline P-GEMOX chemotherapy, 37 of whom also received anti-PD-1 immunotherapy. The application of anti-PD-1 significantly improved progression-free survival (3-year PFS rate 53.9% versus 17.0%, P = 0.009) and overall survival (3-year OS rate 63.7% versus 29.2%, P = 0.01) in the matched NUAT-NKTCL cohort. WES revealed frequent mutations involving immune regulation and genomic instability in immunochemotherapy responders. Our study showed distinct clinical characteristics and mutational profiles in NUAT-NKTCL compared with UAT patients and suggested adding anti-PD-1 immunotherapy in front-line treatment of NUAT-NKTCL. Further studies are needed to validate the efficacy and related biomarkers for immunochemotherapy proposed in this study.
- 20 February 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 829-839
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma
Natural killer/T-cell lymphoma (NKTCL) is a highly heterogeneous disease with a poor prognosis. However, the genomic characteristics and proper treatment strategies for non-upper aerodigestive tract NKTCL (NUAT-NKTCL), a rare subtype of NKTCL, remain largely unexplored. In this study, 1589 patients newly diagnosed with NKTCL at 14 hospitals were assessed, 196 (12.3%) of whom had NUAT-NKTCL with adverse clinical characteristics and an inferior prognosis. By using whole-genome sequencing (WGS) and whole-exome sequencing (WES) data, we found strikingly different mutation profiles between upper aerodigestive tract (UAT)- and NUAT-NKTCL patients, with the latter group exhibiting significantly higher genomic instability. In the NUAT-NKTCL cohort, 128 patients received frontline P-GEMOX chemotherapy, 37 of whom also received anti-PD-1 immunotherapy. The application of anti-PD-1 significantly improved progression-free survival (3-year PFS rate 53.9% versus 17.0%, P = 0.009) and overall survival (3-year OS rate 63.7% versus 29.2%, P = 0.01) in the matched NUAT-NKTCL cohort. WES revealed frequent mutations involving immune regulation and genomic instability in immunochemotherapy responders. Our study showed distinct clinical characteristics and mutational profiles in NUAT-NKTCL compared with UAT patients and suggested adding anti-PD-1 immunotherapy in front-line treatment of NUAT-NKTCL. Further studies are needed to validate the efficacy and related biomarkers for immunochemotherapy proposed in this study.
- Open Access
- 17 February 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-32
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue biopsy is the gold standard for acquiring molecular data and categorizing lymphoma patients into genetic subtypes. However, surgical intervention is unfeasible for patients who are critically ill, have unresectable tumors, or demonstrate low compliance, making tissue biopsies inaccessible to these patients. A critical need for a minimally invasive approach in T-cell lymphoma is evident, particularly in the areas of early diagnosis, prognostic monitoring, treatment response, and drug resistance. Therefore, the clinical application of liquid biopsy techniques has gained significant attention in T-cell lymphoma. Moreover, liquid biopsy requires fewer samples, exhibits good reproducibility, and enables real-time monitoring at molecular levels, thereby facilitating personalized health care. In this review, we provide a comprehensive overview of the current liquid biopsy biomarkers used for T-cell lymphoma, focusing on circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), Epstein-Barr virus (EBV) DNA, antibodies, and cytokines. Additionally, we discuss their clinical application, detection methodologies, ongoing clinical trials, and the challenges faced in the field of liquid biopsy.
- 17 February 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-32
Open AccessLiquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue biopsy is the gold standard for acquiring molecular data and categorizing lymphoma patients into genetic subtypes. However, surgical intervention is unfeasible for patients who are critically ill, have unresectable tumors, or demonstrate low compliance, making tissue biopsies inaccessible to these patients. A critical need for a minimally invasive approach in T-cell lymphoma is evident, particularly in the areas of early diagnosis, prognostic monitoring, treatment response, and drug resistance. Therefore, the clinical application of liquid biopsy techniques has gained significant attention in T-cell lymphoma. Moreover, liquid biopsy requires fewer samples, exhibits good reproducibility, and enables real-time monitoring at molecular levels, thereby facilitating personalized health care. In this review, we provide a comprehensive overview of the current liquid biopsy biomarkers used for T-cell lymphoma, focusing on circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), Epstein-Barr virus (EBV) DNA, antibodies, and cytokines. Additionally, we discuss their clinical application, detection methodologies, ongoing clinical trials, and the challenges faced in the field of liquid biopsy.